High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors

BACKGROUND: Treatment with anti-PD-(L)1 antibodies, approved for several oncology indications, can lead to immune-related adverse events (irAEs). We aimed to investigate risk factors associated with an increased reporting of irAEs in patients treated with PD-(L)1 inhibitors approved for solid tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Gülave, B., Hew, M.N., de Groot, J.S., Rodwell, L., Teerenstra, S., Fabriek, B.O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086026/
https://www.ncbi.nlm.nih.gov/pubmed/33887689
http://dx.doi.org/10.1016/j.esmoop.2021.100107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086026/
https://www.ncbi.nlm.nih.gov/pubmed/33887689
http://dx.doi.org/10.1016/j.esmoop.2021.100107

Ejemplares similares